Background: Symptom association probability (SAP) is thought to distinguish reflux
| INTRODUCTION
Gastro-oesophageal reflux (GERD) occurs when the reflux of gastroduodenal contents leads to troublesome symptoms or complications. 1 The diagnosis of GERD is surprisingly difficult; since current testing (pH and/or impedance monitoring, endoscopy) is neither sensitive nor specific, false negative results are common and can lead to alternative diagnoses and incorrect treatments. 2, 3 Specifically, ambulatory reflux monitoring devices have adequate sensitivity (77%-100%) in patients who have oesophagitis on endoscopy but are less sensitive (0%-71%) among patients without oesophagitis on endoscopy. 2, 3 To improve the sensitivity of pH testing, symptom indices were added to the pH analysis for patients who have normal acid exposure by pH testing and a strong correlation between the timing of their symptoms and reflux events. 4, 5 The role of symptom indices such as symptom association probability (SAP) in the diagnosis of GERD is controversial. [6] [7] [8] [9] These measures are adopted by many experts in the field but the evidence validating their clinical use is sparse. Most studies implicating non-acid reflux or weakly acidic reflux as the aetiology for residual symptoms in patients suspected of having GERD are retrospective or observational. [10] [11] [12] The Rome IV criteria place heavy emphasis on symptom association in distinguishing functional heartburn (normal acid exposure and negative SAP) from reflux hypersensitivity (normal acid exposure and positive SAP). 13, 14 By this reasoning, a patient with a negative pH test but a positive SAP has reflux hypersensitivity and if negative SAP then they have functional heartburn. This distinction has significant clinical implication in suggesting that reflux disease is contributing to the pathophysiology of symptoms in those with "reflux hypersensitivity" and as such encourages escalation of therapies targeted for GERD, including endoscopic or surgical therapies. This intensification occurs despite minimal evidence of SAP correlating with positive outcomes after such therapies (ie Nissen fundoplication).
We have recently shown that symptom indices are not reliable and subject to a high level of variability in patients who have mild reflux parameters or normal oesophageal acid exposure. In patients who have reflux rates less than 10% by pH monitoring (constituting more than 80% of those currently tested), SAP is largely determined by chance occurrence rather than a correlation between symptoms and reflux. Furthermore, the largest assumption in calculating SAP is that patients actually mark exactly when they have symptoms. In a group of patients with chronic cough who underwent time synchronised simultaneous acoustic monitoring and pH-impedance testing, we showed that patients failed to report their true cough events accurately a majority of the time (70%-90%). 15 To more completely understand the difference between the terms "hypersensitive" and "functional", we first evaluated data from a large cohort of patients tested for reflux with both endoscopy and wireless pH monitoring. We quantified the differences in the specific reflux and symptom parameters leading to a diagnosis of SAP positivity or SAP negativity as a measure of clinical relevance of the distinction between reflux hypersensitive and functional diagnoses. We then evaluated a second group of patients 16 who had undergone antireflux surgery to determine whether SAP positivity before surgical intervention (i.e. Nissen or Toupet fundoplication) predicted response to therapy.
| MATERIALS AND METHODS
This study was performed in accordance with the Declaration of Helsinki, Good Clinical practice and applicable regulatory requirements. The Vanderbilt University Institutional Review Board approved the study protocol (IRB# 090872).
| Patient population
The primary study population consisted of patients with upper gas- Fisher's exact test) and considered positive if >95%. Surgical technique used the standard 5-port laparoscopic abdominal set-up. This technique is described in more depth in our group's prior publication. 16 Following antireflux surgery, the primary end point was the time to recurrence of the primary presenting symptom. This was defined by patient report of partial or total recurrence of the original primary presenting symptom at follow-up visits recorded in the patient's chart or by telephone contact. The same return-of-symptom questions were asked by the operating surgeon or gastroenterologist at all post-operative visits or by the study investigators if a follow-up telephone call was warranted.
| Statistical analysis
Demographic and clinical variables were described using the median and access to study data. All analyses were conducted using the R statistical package following principles for reproducible research. 20 3 | RESULTS
| Demographics
A total of 205 patients were studied and stratified into those with erosive oesophagitis (E+; n = 30; LA grade A, n = 14; grade B, n = 9;
grade C, n = 5; and grade D, n = 2), non-erosive but pH+ GERD (EÀ/pH+; n = 130), and non-GERD (EÀ/pHÀ; n = 45; Table 2 ). Age, race, and distribution of symptoms were not statistically different among the groups. Patients with oesophagitis (E+) had significantly (P < 0.001) higher BMI than patients with normal pH testing.
Patients with GERD (E+ and EÀ/pH+) had significantly (P < 0.001) greater acid exposure (total, upright, supine %time pH < 4) than those without GERD (EÀ/pHÀ; Table 2 ).
A separate cohort of 115 patients underwent antireflux surgery. 16 58/115 (50%) patients (34 with typical GERD symptoms, 24
with extra-oesophageal symptoms) had SAP measurements (Table 3) .
Twenty-seven were SAP negative, and 31 were SAP positive. 18/34 with typical GERD symptoms were SAP-positive, while 13/24 with extra-oesophageal symptoms were SAP-positive. A total of 54/58 (94%) of these patients were on twice daily PPI. There was not a statistically significant difference between SAP-positive and SAPnegative groups in partial response to acid suppression therapy.
3.2 | Variability in SAP measurement between day 1 and day 2 
were either SAP-positive on day 1 and SAP-negative on day 2 or SAP-negative on day 1 and SAP-positive on day 2 (18% inconsistency). The inconsistency from day 1 to day 2 in SAP values was most pronounced in patients with oesophagitis positve while it was least in the pHÀ/oesophagitis negative groups (27% in E+, 19% pH+/oesophagitis negative and 7% in pHÀ/oesophagitis negative).
This finding is striking, as patients with objective evidence of reflux have the least consistent correlation of symptoms with reflux. In the pHÀ/oesophagitis negative group, 6/45 (13%) patients were SAPpositive on either day 1 or day 2 and 3/45 (6%) patients were SAP-positive on both days of the pH test monitoring period (Table 4) . Based on Rome IV criteria, these patients would be classified as "hypersensitive."
3.3 | Table parameters for each group and by SAP-positive and SAP-negative status 
| S+R+ parameters by day for oesophagitis negative/pHÀ patients

| DISCUSSION
This study uniquely quantified variables leading to symptom association status of patients undergoing reflux monitoring. We demonstrated that the difference in reflux or symptom parameters between SAP-positive and SAP-negative result was miniscule, regardless of the reflux status of patients. We also showed there is variability in SAP measurement from day 1 to day 2 thus leading to varied diagnosis for each monitored day. We determined that the number of 2-minute intervals for each of the four windows of 2 9 2 table, which distinguished the label functional from hypersensitive, is very small. Finally, we demonstrated that SAP positivity was not predictive of success after Nissen fundoplication.
Clinically, when a patient presents with typical or atypical GERD symptoms, the first course of action is empiric treatment with PPI. 21, 22 It is only after failure of approximately 2 months of PPI therapy to resolve symptoms that reflux testing is considered-generally to rule out GERD as the putative diagnosis. When reflux testing is performed, the recommendation is that it be done off PPI for at least 7 days 21 as 90%-99% of patients will have normal oesophageal acid exposure on PPI therapy. 11, 17 The results of reflux testing are then used to make decisions about future treatments. 22, 23 This could be problematic if patients are diagnosed with GERD based on suboptimal criteria.
Our study focuses on the use of SAP in the interpretation of pH testing. SAP was adopted because "it was a simple statistical method and that it used all relevant observations," 5 but this conclusion is not outcome driven and the patients had not failed PPI therapy before testing. Taghavi In our study, we confirm prior results from Slaughter et al 6 and others that there is day-to-day variability in SAP measurements. We showed that many patients (regardless of group) are SAP-positive on one day and SAP-negative on the other day. In additon, this study is the first of its kind in quantifying the difference between what we believe is artificially defined as "hypersensitive" and "functional" by Rome IV criteria. 13, 14 We showed that in patients with normal pH testing, the mean difference in two minute intervals where symptom and reflux correlated is 0.48% and does not vary significantly based on typical vs atypical reflux symptoms. 0.48% represents a difference in approximately 6.9 S+R+ intervals, which is a very small number of times for a patient to press a button over 2 days. Given the concerns of accurate patient reporting previously mentioned, such a small percentage difference between an oesophagus considered "hypersensitive" and an oesophagus considered "functional" should not influence clinical decision making, especially when it could lead to a surgical procedure. Our surgical outcome data support this conclusion showing that pre-surgical SAP values did not predict response to surgical outcome. Thus, even if the differences in number of S+R+ intervals are statistically significant, it is unlikely that they are clinically significant given that there is no effect on clinical outcome after fundoplication.
One caveat to this finding is that all of our patients undergoing Nissen fundoplication had positive pH testing (as it is not common practice, including our group, to perform fundoplication on patients with negative pH testing), while the group of patients we have highlighted are those with negative pH testing. However, our argument is that if SAP positivity did not correlate with improved outcomes in patients with positive pH testing, it is unlikely that it will in patients with negative pH testing. A second limitation is that the chief complaints of those patients in the EÀ/pHÀ group did not include chest pain. SAP was originally meant to help physicians assess whether chest pain could be attributed to GERD. Further studies will be needed to delineate the use of SAP in these patients.
In addition, if one examines the patients with oesophagitis that underwent pH testing, 8 of the 30 patients were classified as "functional," implying that symptoms and reflux did not correlate on either day (ie SAP-negative on both day 1 and 2), despite objective evidence of reflux during endoscopy. One can interpret this information in one of two ways: either the SAP metric is not accurately capturing symptom-reflux correlation in patients with confirmed reflux or symptom-reflux correlation does not predict whether or not reflux is occurring. Both interpretations are problematic.
Finally, our data add to the evolving literature regarding the nature of SAP as a diagnostic tool. Differences in symptom-reflux correlation creating SAP positivity are small, vary from day to day, and do not correlate with improved outcomes after fundoplication. We propose that the distinction between "hypersensitive" and "functional" definition is artificial, at least as quantified by SAP. When the chief complaint is heartburn, regurgitation, or cough, our recommendation is that SAP is not clinically useful.
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